Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients

Clicks: 346
ID: 119970
1998
Between July 1993 and September 1996, 107 consecutive febrile episodes in 83 neutropenic cancer patients with a median age of 41 years were randomized to treatment either with piperacillin/tazobactam 4.5 g every 8 h i.v. or ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day. In the case o …
Reference Key
u1998supportivemonotherapy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hess U;Böhme C;Rey K;Senn HJ;;
Journal Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Year 1998
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9695210
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine prognosis treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged Comparative Study Prospective Studies Clinical Trial Randomized Controlled Trial chi-square distribution anti-bacterial agents / administration & dosage* ceftazidime / adverse effects drug therapy combination fever / drug therapy* neoplasms / complications* neutropenia / drug therapy* fever / etiology neutropenia / etiology analysis of variance penicillanic acid / administration & dosage penicillanic acid / analogs & derivatives* tazobactam treatment failure pmid:9695210 doi:10.1007/s005200050184 u hess c böhme h j senn amikacin / administration & dosage* amikacin / adverse effects ceftazidime / administration & dosage* enzyme inhibitors / administration & dosage* enzyme inhibitors / adverse effects penicillanic acid / adverse effects piperacillin / administration & dosage* piperacillin / adverse effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.